A drug for Alzheimer’s disease that seems to work

to be cynical about announcements of drugs that claim to slow the progress of Alzheimer’s disease, the most common form of . Lecanemab, however, may be the real deal. Results of a clinical trial, conducted by its makers, Eisai, of Tokyo, and Biogen, of Cambridge, Massachusetts, have just been announced in the . After 18 months, it had slowed the progress of symptoms by a quarter.